耐碳青霉烯类肠杆菌科细菌的分布特点与耐药性分析

发布时间：2018-11-16 14:28

【摘要】：目的了解2013-2014年耐碳青霉烯类肠杆菌科细菌(CRE)的分布特点及其耐药性,为指导临床合理用药提供依据。方法收集2013年1月-2014年12月临床分离CRE,采用自动化仪器方法和纸片扩散法(K-B法)对上述菌株进行药物敏感性试验,药敏结果严格按照美国临床实验室标准化研究所(CLSI)或FDA标准进行判定;采用WHONET软件对数据进行统计分析。结果共收集临床分离CRE 538株,主要包括肺炎克雷伯菌222株占41.3%、大肠埃希菌72株占13.4%;CRE主要标本来源为呼吸道,共181株占33.6%;CRE除对阿米卡星和替加环素耐药率较低外,对其他抗菌药物的耐药率均40.0%。结论 CRE对多数常用抗菌药物呈现耐药,给临床抗感染治疗带来严峻挑战,应加强对CRE的耐药性监测,并采取有效措施预防和控制此类耐药菌的传播。
[Abstract]:Objective to investigate the distribution and drug resistance of Enterobacteriaceae (CRE) resistant to carbapenem from 2013 to 2014, and to provide evidence for guiding rational drug use in clinic. Methods Clinical isolates of CRE, from January 2013 to December 2014 were collected for drug sensitivity tests using automated instrument method and disk diffusion method (K-B method). The drug sensitivity results were determined strictly according to (CLSI) or FDA standards of American Institute of Clinical Laboratory Standardization. The data were analyzed by WHONET software. Results A total of 538 clinical isolates of CRE were collected, including 222strains of Klebsiella pneumoniae (41.3%), 72 strains of Escherichia coli (13.4C), mainly from respiratory tract, and 181 strains (33.6B). The resistance rates of CRE to other antimicrobial agents except for amikacin and tegicycline were lower than those to amikacin and tegicycline respectively. Conclusion CRE is resistant to most commonly used antimicrobial agents, which brings severe challenge to clinical anti-infection treatment. It is necessary to strengthen the monitoring of drug resistance to CRE and to take effective measures to prevent and control the spread of this kind of drug-resistant bacteria.
【作者单位】：解放军第二军医大学附属上海长海医院感染控制科;解放军第二军医大学附属上海长海医院实验诊断科;
【基金】：“十二五”国家科技重大专项基金资助项目(2013ZX10003009)
【分类号】：R446.5

【参考文献】